Roeland Lameris, researcher within Amsterdam UMC’s Cancer Center Amsterdam published an article about a potential new immunotherapeutic strategy.
Findings in the paper highlight the potential for a LAVA-derived antibody fragment, known as a single domain antibody, that acts as a bridge to link together two key immune cell receptors – the CD1d receptor and the T cell receptor of natural killer T (NKT) cells – in order to enhance the body’s immune response to cancer. The CD1d receptor is frequently expressed by tumor cells and NKT cells are positioned at the interface between the innate and adaptive immune system and play an important role in the host-rejection of both tumors and virally infected cells. Preclinical research through the companies’ collaboration demonstrates that a CD1d-NKT cell targeting antibody resulted in significant activation of NKT cells and the subsequent killing of CD1d-expressing tumor cells in multiple tumor samples, including multiple myeloma and acute myeloid leukemia.
Link to read the article: https://www.nature.com/articles/s43018-020-00111-6
And for a background link to the press release that Lava Therapeutics (the start-up biotech that originates from our department) has issued about it: : https://lavatherapeutics.com/news/lava-therapeutics-amsterdam-umc-and-monash-university-announce-publication-of-a-novel-cancer-immunotherapy-approach-in-nature-cancer/